Insurance denials for new hepatitis C drugs remain high nationwide, study suggests

(Infectious Diseases Society of America) Highly effective drugs that can cure chronic hepatitis C infection in approximately 95 percent of patients first became available in the US in 2014. But both public and private insurers continue to deny coverage for these costly drugs at high rates nationwide, despite efforts to remove treatment restrictions, according to a new study published in Open Forum Infectious Diseases.

Comments
%d bloggers like this: